Lenvatinib is More Effective & Safer Than Sorafenib in the Treatment of Renal Cell Carcinoma - A Single-Center Retrospective Analysis of 70 Cases. Journal of Carcinogenesis, [S. l.], v. 23, n. 1, p. 624–628, 2024. DOI: 10.64149/J.Carcinog.23.1.624-628. Disponível em: https://carcinogenesis.com/index.php/JOC/article/view/1770. Acesso em: 16 jan. 2026.